99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVß3 expression.

This report describes the biologic evaluations of [99mTc(HYNIC-3P-RGD2)(tricine)(TPPTS)] (99mTc-3P-RGD2: 6-hydrazinonicotinyl; 3P-RGD2  =  PEG4-E[PEG4-c(RGDfK)]2; PEG4  =  15-amino-4,7,10,13-tetraoxapentadecanoic acid; and TPPTS  =  trisodium triphenylphosphine-3,3',3''-trisulfonate), [99mTc(HYNIC-3G-RGD2)(tricine)(TPPTS)] (99mTc-3G-RGD2: 3G-RGD2  =  G3-E[G3-c(RGDfK)]2 and G3  =  Gly-Gly-Gly), and 99mTcO(MAG2-3G-RGD2) (MAG2  =  mercaptoacetylglycylglycyl) as radiotracers for noninvasive imaging of tumor integrin αvß3 expression in five xenografted tumor-bearing models. Biodistribution and imaging studies were performed in athymic nude mice bearing U87MG, MDA-MB-435, A549, HT29, or PC-3 tumor xenografts. Immunochemistry was performed using the cultured primary tumor cells and xenografted tumor tissues. It was found that the radiotracer tumor uptake followed the trend U87MG > MDA-MB-435 ≈ HT29 ≈ A549 > PC-3. The total integrin ß3 expression levels followed the general trend: U87MG > MDA-MB-435 ≈ A549∼HT29 > PC-3. There is a linear relationship between the radiotracer injected dose per gram tumor uptake and the total integrin ß3 expression levels. On the basis of these, it was concluded that radiotracer tumor uptake is contributed by integrin αvß3 expressed on tumor cells and activated endothelial cells of the tumor neovasculature. 99mTc-3P-RGD2 has the capability to monitor integrin αvß3 expression in a noninvasive fashion.